Search Results - "Wall, Anna K. M."

Results of a phase 3 study of IVO vs IO for previously untreated older patients (pts) with chronic lymphocytic leukemia (CLL) and impact of COVID-19 (Alliance) by Woyach, Jennifer Ann, Yin, Jun, Brown, Jennifer R., Dinner, Shira, Lozanski, Gerard, Little, Richard F., Miller, Cecelia, Damarla, Vijay Kumar, Coutre, Steve E., Ding, Wei, Hill, Brian T, Perez Burbano, Gabriela, Ruppert, Amy S., Wall, Anna K. M., Feldman, Diane, Dib, Elie G., Erba, Harry Paul, Litzow, Mark Robert, Stone, Richard M., Byrd, John C.

“…7500 Background: The Bruton’s tyrosine kinase inhibitor (BTKi) ibrutinib +/- anti-CD20 antibody obinutuzumab (IO) is a standard frontline regimen for older…”
Get full text

Comparison of clinical scoring systems in aggressive B-cell lymphomas (BCL): An individual patient-level analysis across international trials (SEAL) by Ruppert, Amy S., Dixon, Jesse G., Salles, Gilles A., Wall, Anna K. M., Cunningham, David, Poeschel, Viola, Haioun, Corinne, Tilly, Herve, Ghesquieres, Herve, Ziepert, Marita, Flament, Jocelyne, Flowers, Christopher, Shi, Qian, Shmitz, Norbert

“…Abstract only 7544 Background: Great heterogeneity in survival exists for patients (pts) newly diagnosed with aggressive BCL. Three scoring systems based on…”
Get full text